Furthermore, the fact that patients suffering from FTD can have protein inclusion pathology that is positive for either TDP-43, τ-protein, or FUS (Ling et al., 2013), and that ~15% of ALS patients are estimated to develop cognitive deficits meeting FTD criteria (Ringholz et al., 2005), is striking evidence of both pathological and symptomatic overlap. This evidence concerns the gene TBXT and amyotrophic lateral sclerosis.